Estrada, Vicente
Górgolas, Miguel
Peña, José A.
Tortajada, Elena
Castro, Antonio
Presa, María http://orcid.org/0000-0001-5925-0619
Oyagüez, Itziar
Funding for this research was provided by:
Gilead Sciences Spain
Article History
Accepted: 10 January 2022
First Online: 5 February 2022
Declarations
:
: This study was funded by Gilead Sciences, Spain.
: VE has received fees from Gilead Sciences, Janssen, Merck Sharp & Dohme Corp. (MSD) and ViiV Healthcare for lectures, including service on speakers’ bureaus. MG has received grants from ViiV Healthcare and fees from Gilead Sciences, Janssen and ViiV Healthcare for consulting work, participation in review activities and lectures, including service on speakers’ bureaus. JAP has no conflicts of interest to declare. ET has received fees from Gilead Sciences for expert testimony. AC is a full-time employee of Gilead Sciences. MP and IO are employees of Pharmacoeconomics & Outcomes Research Iberia (PORIB), a consultancy firm specializing in health technology assessment, which has received unconditional funding from Gilead Sciences.
: Not applicable.
: Not applicable.
: Not applicable.
: All data used to develop the model are displayed in the manuscript.
: Data are available from the corresponding author upon reasonable request.
: VE, MG, JAP and ET validated the parameters included in this analysis. MP performed the analysis. MP and IO drafted the manuscript. All authors participated in the interpretation of the results, and reviewed and approved the final manuscript.